how does CRISPR Cas9 gene editing work

Core Mechanism

demonstrated that Cas9 from Streptococcus pyogenes can be programmed with a guide RNA to cleave specific DNA sites, where a dual-RNA structure directs Cas9 to introduce double-strand breaks (DSBs) at specific genomic locations.

.

System Pipeline (ASCII Diagram)

╔══════════════════════════════════════════════════════════════════╗ ║ CRISPR-Cas9 GENE EDITING PIPELINE ║ ╚══════════════════════════════════════════════════════════════════╝

STEP 1: COMPONENT DESIGN & ASSEMBLY ┌─────────────────────┐ ┌──────────────────────────┐ │ Guide RNA (gRNA) │ │ Cas9 Protein │ │ ┌───────────────┐ │ │ ┌────────────────────┐ │ │ │ crRNA (~20bp) │ │ │ │ HNH nuclease │ │ │ │ (target- │ │ │ │ domain │ │ │ │ specific) │ │ │ │ RuvC nuclease │ │ │ └──────┬────────┘ │ │ │ domain │ │ │ ┌──────▼────────┐ │ │ │ PAM-interacting │ │ │ │ tracrRNA │ │ │ │ domain │ │ │ │ (scaffold) │ │ │ └────────────────────┘ │ │ └───────────────┘ │ └────────────┬─────────────┘ └──────────┬──────────┘ │ │ │ └──────────┬─────────────────┘ ▼ ┌─────────────────┐ │ Cas9-gRNA │ │ Ribonucleopro- │ │ tein Complex │ └────────┬────────┘ │ ▼

STEP 2: TARGET RECOGNITION ┌──────────────────────────────────────────────────────────┐ │ GENOMIC DNA │ │ 5'─────────────[TARGET SEQUENCE]─[NGG]──────────── 3' │ │ 3'─────────────[COMPLEMENT ]─[NCC]──────────── 5' │ │ └──┘ │ │ PAM │ │ (required for binding) │ └──────────────────────────────────────────────────────────┘ │ │ gRNA base-pairs with target strand │ PAM verified by Cas9 PAM-interacting domain ▼ ┌──────────────────────────────────────────────────────────┐ │ R-LOOP FORMATION │ │ 5'─────────[gRNA:DNA heteroduplex]──[NGG]────────── 3' │ │ 3'─────────[displaced strand ]──[NCC]────────── 5' │ └──────────────────────────────────────────────────────────┘

STEP 3: DNA CLEAVAGE (Double-Strand Break) ┌──────────────────────────────────────────────────────────┐ │ HNH domain ──cuts──▶ complementary strand │ │ RuvC domain ──cuts──▶ non-complementary strand │ │ │ │ 5'────────────────────── ╳ ─────────────────────── 3'│ │ 3'────────────────────── ╳ ─────────────────────── 5'│ │ └─DSB─┘ │ └──────────────────────────────────────────────────────────┘

STEP 4: CELLULAR DNA REPAIR (two pathways) │ ┌───────┴────────┐ ▼ ▼ ┌──────────┐ ┌────────────────────────────┐ │ NHEJ │ │ HDR │ │(error- │ │ (template-directed repair)│ │ prone) │ │ │ │ │ │ Requires: donor template │ │ Result: │ │ Result: precise edit, │ │ Indels │ │ correction, or insertion │ │ → gene │ │ → gene correction │ │ knockout│ │ │ └──────────┘ └────────────────────────────┘

STEP 5: OUTCOME VERIFICATION ┌──────────────────────────────────────────────────────────┐ │ Detection of modifications (NHEJ or HDR confirmed) │ │ Assessment of off-target effects at non-intended loci │ └──────────────────────────────────────────────────────────┘

─────────────────── ADVANCED MODES ────────────────────────

dCas9 (catalytically dead) ──▶ no cleavage │ ├──▶ Gene REGULATION (activation/repression) ├──▶ Epigenetic EDITING (e.g., DNA methylation) └──▶ Genome IMAGING

Base Editors (Cas9 + deaminase) ──▶ C→T or A→G [no DSB]

Prime Editors (Cas9 nickase + RT + pegRNA) ──▶ all 12 point mutations + small indels [no DSB]

Key Steps Explained

. Ran et al. (2013) further established a step-by-step protocol for adapting this system to eukaryotic cells, including guide RNA design and delivery.

DNA Repair Outcomes After Cas9 generates a DSB, cellular repair proceeds via two routes : error-prone non-homologous end joining (NHEJ), producing insertions or deletions (indels) that typically knock out a gene; or homology-directed repair (HDR), which uses a supplied donor template to introduce precise edits.

Beyond Simple Cleavage Wang et al. (2016) describe how the nuclease-deactivated form (dCas9) provides a versatile RNA-guided DNA-targeting platform for gene regulation, epigenetic rewriting, and imaging — all without cutting the genome. Vojta et al. (2016) demonstrated one such application: fusing dCas9 to the DNMT3A methyltransferase domain to achieve targeted CpG methylation in a ~35 bp window at a specified locus.

Komor et al. (2016) introduced base editors — fusions of Cas9 and a cytidine deaminase — enabling direct, irreversible conversion of one target DNA base into another without requiring a DSB or donor template. Anzalone et al. (2019) then described prime editing, which uses a reverse transcriptase fused to Cas9 nickase together with a prime editing guide RNA to write new genetic information into a specified site, enabling all 12 types of point mutations as well as small insertions and deletions, again without DSBs or donor DNA.

Off-Target Risk A major concern in all applications is off-target effects — unexpected or unwanted alterations deposited elsewhere in the genome . Guo et al. (2023) summarize methods developed to detect off-target sites and describe upgraded Cas9 derivatives engineered for enhanced precision.

Clinical Translation Frangoul et al. (2021) reported a phase 1/2 trial (CTX001) in which CRISPR-Cas9-edited autologous hematopoietic stem cells were used to induce fetal hemoglobin production, eliminating disease manifestations in patients with transfusion-dependent β-thalassemia and severe sickle cell disease — illustrating the pathway from mechanism to therapy.